Enhancement of lung levels of antibiotics by ambroxol and bromhexine

Major unmet needs remain for improved Antibiotic treatment in lung infections. While development of new Antibiotics is needed to overcome resistance, other approaches to optimize therapy using existing agents are also attractive. Ambroxol induces lung Autophagy at human-relevant doses and improves lung levels of several approved Antibiotics. Areas covered: This review discusses preclinical and clinical studies of the effects of ambroxol (and its prodrug precursor bromhexine) co-treatment upon levels of Antibiotics in lung tissue, sputum, and bronchoalveolar lavage fluid. Expert opinion: Ambroxol co-treatment is associated with significant increases in lung tissue and airway surface fluid levels of a range of Antibiotics including beta lactams, glycopeptides, macrolides, nitrofurans, and rifamycins. In most cases, the increased levels are only modest and are insufficient to overcome high-level resistance against that same Antibiotic class, and so co-treatment with ambroxol is unlikely to alter clinical outcomes. Additionally, for most Antibiotics there is no evidence that outcomes in non-resistant disease are improved by higher drug levels, and there is limited efficacy of co-treatment of Antibiotics with ambroxol for most pathogens. The two cases where ambroxol may improve therapy are rifampin-sensitive tuberculosis and non-tuberculous mycobacterial Infection, and vancomycin sensitive methicillin resistant Staphylococcus aureus pneumonia.